학술논문
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
Document Type
article
Author
Chiara Cattaneo; Jon Salmanton-García; Francesco Marchesi; Shaimaa El-Ashwah; Federico Itri; Barbora Weinbergerová; Maria Gomes Da Silva; Michelina Dargenio; Julio Dávila-Valls; Sonia Martín-Pérez; Francesca Farina; Jaap Van Doesum; Toni Valković; Caroline Besson; Christian Bjørn Poulsen; Alberto López-García; Pavel Žák; Martin Schönlein; Klára Piukovics; Ozren Jaksic; Alba Cabirta; Natasha Ali; Uluhan Sili; Nicola Fracchiolla; Giulia Dragonetti; Tatjana Adžić-Vukičević; Monia Marchetti; Marina Machado; Andreas Glenthøj; Olimpia Finizio; Fatih Demirkan; Ola Blennow; Maria Chiara Tisi; Ali S. Omrani; Milan Navrátil; Zdeněk Ráčil; Jan Novák; Gabriele Magliano; Moraima Jiménez; Carolina Garcia-Vidal; Nurettin Erben; Maria Ilaria Del Principe; Caterina Buquicchio; Rui Bergantim; Josip Batinić; Murtadha Al-Khabori; Luisa Verga; Tomáš Szotkowski; Michail Samarkos; Irati Ormazabal-Vélez; Stef Meers; Johan Maertens; László Imre Pinczés; Martin Hoenigl; Ľuboš Drgoňa; Annarosa Cuccaro; Yavuz M. Bilgin; Avinash Aujayeb; Laman Rahimli; Stefanie Gräfe; Mariarita Sciumè; Miloš Mladenović; Gökçe Melis Çolak; Maria Vittoria Sacchi; Anna Nordlander; Caroline Berg Venemyr; Michaela Hanáková; Nicole García-Poutón; Ziad Emarah; Giovanni Paolo Maria Zambrotta; Raquel Nunes Rodrigues; Raul Cordoba; Gustavo-Adolfo Méndez; Monika M. Biernat; Oliver A. Cornely; Livio Pagano
Source
Cancers, Vol 14, Iss 22, p 5530 (2022)
Subject
Language
English
ISSN
14225530
2072-6694
2072-6694
Abstract
Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.